Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Conference Call February 28, 2024 8:00 AM ET
Company Participants
Cristi Barnett - Corporate Communications and IR
Gilmore O'Neill - CEO
Baisong Mei - CMO
Erick Lucera - CFO
Linda Burkly - CSO
Caren Deardorf - Chief Commercial and Strategy Officer
Conference Call Participants
Joon Lee - Truist Securities
Samantha Semenkow - Citi
Brian Cheng - JPMorgan
Greg Harrison - Bank of America
Mani Foroohar - Leerink
Max Skor - Morgan Stanley
Gena Wang - Barclays
Dae Gon Ha - Stifel
Ry Forseth - Guggenheim
Phil Nadeau - TD Cowen
Jay Olson - Oppenheimer & Co.
Yanan Zhu - Wells Fargo
Luca Issi - RBC Capital
Timur Ivannikov - Raymond James
Jack Allen - Baird
Operator
Good morning, and welcome to Editas Medicine's Fourth Quarter and Full Year 2023 Conference Call. All participants are now in listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded at the company's request.
I would now like to turn the call over to Cristi Barnett, Corporate Communications and Investor Relations at Editas Medicine.
Cristi Barnett
Thank you, Maria. Good morning, everyone, and welcome to our fourth quarter and full year 2023 conference call.
Earlier this morning, we issued a press release providing our financial results and recent corporate updates. A replay of today's call will be available in the Investors section of our website approximately two hours after its completion. After our prepared remarks, we will open the call for Q&A.
As a reminder, various remarks that we make during this call about the company's future expectations, plans and prospects constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our most recent Annual Report on Form 10-K, which is on file with the SEC as updated by our subsequent filings.
In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. Except as required by law, we specifically disclaim any obligation to update or revise any forward-looking statements, even if our views change.
Now, I will turn the call over to our CEO, Gilmore O'Neill.